Program
Preclinical
Phase 1
Phase 2
Phase 3
Status
Alzheimer's Disease
Early-to-mild Alzheimer’s disease (AD)
enrollment target met
Completed Studies
Zervimesine: Targeting Toxic Protein Binding in Neural Pathways
The age-related buildup of toxic protein oligomers – including amyloid beta (Aβ) and alpha-synuclein – drives the progression of several neurodegenerative diseases, including DLB and Alzheimer’s disease. As these toxic oligomers accumulate, they interfere with normal brain function, leading to cognitive and functional decline.

Zervimesine (CT1812), our investigational, small-molecule oral therapy, has been shown to prevent toxic oligomers from binding to neurons by way of the sigma-2 receptor. This oligomer-focused mechanism of action has great potential to protect synaptic integrity and function in patients with challenging neurodegenerative diseases.
Sigma-2: A Key Neuronal Receptor
The sigma-2 receptor complex, found in brain and retinal cells, is being investigated for its potential role in helping slow or prevent synaptic damage in age-related neurodegenerative diseases, including DLB and Alzheimer’s.
Preclinical and early clinical data demonstrate that the sigma-2 receptor enables toxic protein oligomers to cause progressive neuronal decline. This discovery suggests a novel approach to treating neurodegenerative diseases, by shielding synapses from oligomer-related damage.